Aimmune Therapeutics Inc (AIMT) Stake Lowered by C WorldWide Group Holding A S

C WorldWide Group Holding A S decreased its stake in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) by 46.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 123,700 shares of the biotechnology company’s stock after selling 107,200 shares during the quarter. C WorldWide Group Holding A S’s holdings in Aimmune Therapeutics were worth $4,678,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Daiwa SB Investments Ltd. grew its position in shares of Aimmune Therapeutics by 44.5% during the 4th quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock worth $276,000 after buying an additional 2,245 shares during the period. Teacher Retirement System of Texas acquired a new stake in shares of Aimmune Therapeutics during the 4th quarter worth approximately $282,000. Legal & General Group Plc grew its position in shares of Aimmune Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after buying an additional 1,634 shares during the period. SG Americas Securities LLC grew its position in shares of Aimmune Therapeutics by 54.7% during the 3rd quarter. SG Americas Securities LLC now owns 8,430 shares of the biotechnology company’s stock worth $209,000 after buying an additional 2,979 shares during the period. Finally, Voya Investment Management LLC grew its position in Aimmune Therapeutics by 31.2% in the 2nd quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock valued at $324,000 after purchasing an additional 3,757 shares during the period. 73.54% of the stock is owned by institutional investors.

Aimmune Therapeutics Inc (NASDAQ:AIMT) opened at $38.68 on Friday. The stock has a market cap of $1,970.00 and a price-to-earnings ratio of -16.53. Aimmune Therapeutics Inc has a fifty-two week low of $15.97 and a fifty-two week high of $40.65.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.09. analysts predict that Aimmune Therapeutics Inc will post -2.51 EPS for the current year.

Several research firms recently issued reports on AIMT. BidaskClub raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Royal Bank of Canada began coverage on shares of Aimmune Therapeutics in a research report on Wednesday. They issued an “outperform” rating and a $55.00 price target for the company. Roth Capital lifted their price target on shares of Aimmune Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Zacks Investment Research raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 31st. Finally, Credit Suisse Group set a $45.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Thursday, January 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $57.25.

In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 1,906 shares of Aimmune Therapeutics stock in a transaction on Monday, December 4th. The shares were sold at an average price of $38.66, for a total transaction of $73,685.96. Following the transaction, the insider now directly owns 1,906 shares of the company’s stock, valued at approximately $73,685.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Douglas T. Sheehy sold 1,648 shares of Aimmune Therapeutics stock in a transaction on Monday, February 5th. The stock was sold at an average price of $35.87, for a total transaction of $59,113.76. The disclosure for this sale can be found here. Insiders have sold a total of 134,294 shares of company stock worth $5,097,144 over the last ninety days. Insiders own 24.56% of the company’s stock.

WARNING: This piece was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/02/10/aimmune-therapeutics-inc-aimt-stake-lowered-by-c-worldwide-group-holding-a-s.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics Inc (NASDAQ:AIMT).

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply